These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 16617322)

  • 1. The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow.
    Ingram W; Lea NC; Cervera J; Germing U; Fenaux P; Cassinat B; Kiladjian JJ; Varkonyi J; Antunovic P; Westwood NB; Arno MJ; Mohamedali A; Gaken J; Kontou T; Czepulkowski BH; Twine NA; Tamaska J; Csomer J; Benedek S; Gattermann N; Zipperer E; Giagounidis A; Garcia-Casado Z; Sanz G; Mufti GJ
    Leukemia; 2006 Jul; 20(7):1319-21. PubMed ID: 16617322
    [No Abstract]   [Full Text] [Related]  

  • 2. Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activation.
    Aboudola S; Murugesan G; Szpurka H; Ramsingh G; Zhao X; Prescott N; Tubbs RR; Maciejewski JP; Hsi ED
    Am J Surg Pathol; 2007 Feb; 31(2):233-9. PubMed ID: 17255768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histological and molecular classification of chronic myeloproliferative disorders in the age of JAK2: persistence of old questions despite new answers.
    Hussein K; Bock O; Kreipe H
    Pathobiology; 2007; 74(2):72-80. PubMed ID: 17587878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
    Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequent detection of the JAK2 V617F mutation in bone marrow core biopsy specimens from chronic myeloproliferative disorders using the TaqMan polymerase chain reaction single nucleotide polymorphism genotyping assay: a retrospective study with pathologic correlations.
    Bousquet M; Le Guellec S; Quelen C; Rigal-Huguet F; Delsol G; Brousset P
    Hum Pathol; 2006 Nov; 37(11):1458-64. PubMed ID: 16949922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders.
    Rumi E; Passamonti F; Pietra D; Della Porta MG; Arcaini L; Boggi S; Elena C; Boveri E; Pascutto C; Lazzarino M; Cazzola M
    Cancer; 2006 Nov; 107(9):2206-11. PubMed ID: 16998940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JAK2(V617F) mutation in myelodysplastic syndrome (MDS) with del(5q) arises in genetically discordant clones.
    Sokol L; Caceres G; Rocha K; Stockero KJ; Dewald DW; List AF
    Leuk Res; 2010 Jun; 34(6):821-3. PubMed ID: 19819015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High prevalence of the JAK2 V617F mutation in patients with extrahepatic portal vein thrombosis.
    De Stefano V; Fiorini A; Rossi E; Za T; Chiusolo P; Sica S; Leone G
    Hepatology; 2007 Mar; 45(3):831-2; author reply 832-3. PubMed ID: 17326212
    [No Abstract]   [Full Text] [Related]  

  • 9. Detection of the activating JAK2 V617F mutation in paraffin-embedded trephine bone marrow biopsies of patients with chronic myeloproliferative diseases.
    Horn T; Kremer M; Dechow T; Pfeifer WM; Geist B; Perker M; Duyster J; Quintanilla-Martinez L; Fend F
    J Mol Diagn; 2006 Jul; 8(3):299-304. PubMed ID: 16825501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status.
    Medinger M; Skoda R; Gratwohl A; Theocharides A; Buser A; Heim D; Dirnhofer S; Tichelli A; Tzankov A
    Br J Haematol; 2009 Jul; 146(2):150-7. PubMed ID: 19466975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone marrow mesenchymal stromal cells of patients with myeloproliferative disorders do not carry the JAK2-V617F mutation.
    Mercier F; Monczak Y; François M; Prchal J; Galipeau J
    Exp Hematol; 2009 Mar; 37(3):416-20. PubMed ID: 19135773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The unclassifiable myeloproliferative neoplasm--morphological, cytogenetic and clinical features].
    Borovecki A; Skrtić A; Paro MM; Lasan R; Dominis M
    Acta Med Croatica; 2011 Sep; 65 Suppl 1():31-6. PubMed ID: 23126027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The JAK2 V617F mutation is rare in RARS but common in RARS-T.
    Ceesay MM; Lea NC; Ingram W; Westwood NB; Gäken J; Mohamedali A; Cervera J; Germing U; Gattermann N; Giagounidis A; Garcia-Casado Z; Sanz G; Mufti GJ
    Leukemia; 2006 Nov; 20(11):2060-1. PubMed ID: 16932338
    [No Abstract]   [Full Text] [Related]  

  • 14. Evaluation of JAK2 in B and T cell neoplasms: identification of JAK2(V617F) mutation of undetermined significance (JMUS) in the bone marrow of three individuals.
    Wang YL; Lee JW; Kui JS; Chadburn A; Cross NC; Knowles DM; Coleman M
    Acta Haematol; 2007; 118(4):209-14. PubMed ID: 18032883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Janus kinase 2 V617F mutation is detectable in spleen of patients with chronic myeloproliferative diseases suggesting a malignant nature of splenic extramedullary hematopoiesis.
    Konoplev S; Hsieh PP; Chang CC; Medeiros LJ; Lin P
    Hum Pathol; 2007 Dec; 38(12):1760-3. PubMed ID: 17707884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of JAK2(V617F) mutation in Chinese patients with myeloproliferative disorders.
    Chen S; Fei H; Zhang R; Xue Y; Pan J; Wu Y; Ceng J
    Am J Hematol; 2007 Jun; 82(6):458-9. PubMed ID: 17266061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What is the role of JAK2(V617F) mutation in leukemic transformation of myeloproliferative neoplasms?
    Lopes da Silva R; Ribeiro P; Lourenço A; Santos SC; Santos M; Costa I; de Sousa AB
    Lab Hematol; 2011 Mar; 17(1):12-6. PubMed ID: 21421540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The JAK2 V617F mutation occurs frequently in myelodysplastic/myeloproliferative diseases, but is absent in true myelodysplastic syndromes with fibrosis.
    Kremer M; Horn T; Dechow T; Tzankov A; Quintanilla-Martínez L; Fend F
    Leukemia; 2006 Jul; 20(7):1315-6. PubMed ID: 16617316
    [No Abstract]   [Full Text] [Related]  

  • 19. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.
    Hoermann G; Cerny-Reiterer S; Herrmann H; Blatt K; Bilban M; Gisslinger H; Gisslinger B; Müllauer L; Kralovics R; Mannhalter C; Valent P; Mayerhofer M
    FASEB J; 2012 Feb; 26(2):894-906. PubMed ID: 22051730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlations of JAK2-V617F mutation with clinical and laboratory findings in patients with myeloproliferative disorders.
    Speletas M; Katodritou E; Daiou C; Mandala E; Papadakis E; Kioumi A; Ritis K; Korantzis I
    Leuk Res; 2007 Aug; 31(8):1053-62. PubMed ID: 17045648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.